Insider Shareholders with Direct Ownership of An2 Therapeutics, Inc. (ANTX)
This section provides a comprehensive overview of the insiders with direct ownership of An2 Therapeutics, Inc. (ANTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
AN2 Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 0 | 214,777 | 2,184,224 $2.49 Million | 11 |
Jun 06, 2022
Reduced 1.2%
|
|
|
Eric Easom
Chief Executive Officer |
259,157 | 97,008 | 256,380 $292,273 | 21 |
Jun 02, 2025
Added 3.75%
|
| 180,000 | 12,482 | 177,353 $202,182 | 6 |
Nov 04, 2025
Reduced 1.56%
|
|
| 145,538 | 0 | 145,538 $165,913 | 6 |
Apr 10, 2025
Added 6.74%
|
|
|
Sanjay Chanda
Chief Development Officer |
77,750 | 2,957 | 80,074 $91,284 | 3 |
Feb 26, 2025
Added 38.56%
|
|
Lucy Day
Chief Financial Officer |
74,000 | 2,957 | 79,170 $90,253 | 3 |
Feb 26, 2025
Added 37.0%
|
|
Stephen David Prior
Chief Strategy Officer |
38,125 | 2,794 | 65,548 $74,724 | 4 |
Nov 04, 2025
Reduced 1.15%
|
| 40,919 | 0 | 63,749 $72,673 | 4 |
Oct 10, 2025
Added 13.99%
|
|
|
Paul Eckburg
Chief Medical Officer |
30,000 | 0 | 51,416 $58,614 | 1 |
Mar 15, 2024
Added 36.85%
|
| 40,919 | 0 | 40,919 $46,647 | 4 |
Oct 10, 2025
Added 20.21%
|
|
|
Kevin Michael Krause
Chief Strategy Officer |
40,000 | 10,000 | 31,914 $36,381 | 5 |
Mar 15, 2024
Added 48.45%
|
| 13,255 | 0 | 13,255 $15,110 | 4 |
Oct 10, 2025
Added 19.81%
|
|
| 9,077 | 0 | 9,077 $10,347 | 1 |
Dec 19, 2024
Added 50.0%
|
|
| 8,610 | 0 | 8,610 $9,815 | 1 |
May 28, 2025
Added 50.0%
|
|